Akira Toriihara1, Lucia Baratto1, Tomomi Nobashi1, Sonya Park1, Negin Hatami1, Guido Davidzon1, Pamela L Kunz2, Andrei Iagaru3. 1. Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5281, USA. 2. Division of Oncology, Department of Medicine, Stanford University, 875 Blake Wilbur Dr, Stanford, CA, 94305-5826, USA. 3. Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, CA, 94305-5281, USA. aiagaru@stanford.edu.
Abstract
PURPOSE: To evaluate the prognostic value of volumetric parameters calculated from 68Ga-1,4,7,10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA)-Thr3-octreotate (68Ga-DOTATATE) positron emission tomography/computed tomography (PET/CT) in patients with well-differentiated neuroendocrine tumor (WD-NET). METHODS: Ninety-two patients (44 men and 48 women, mean age of 59.5-year-old) with pathologically confirmed WD-NET (grades 1 or 2) were enrolled in a prospective expanded access protocol. Selected data was analyzed retrospectively for this project. Maximum standardized uptake value (SUVmax) in the lesion with the highest 68Ga-DOTATATE uptake was measured and recorded for each patient. In addition, two volumetric parameters, namely, somatostatin receptor expressing tumor volume (SRETV) and total lesion somatostatin receptor expression (TLSRE), were calculated in each 68Ga-DOTATATE-avid lesion. SRETV was defined as tumor volume with higher 68Ga-DOTATATE uptake than the 50% of SUVmax within the volume of interest (VOI) for each lesion. TLSRE was calculated by multiplying SRETV and mean SUV within the same VOI. Thereafter, the sum of SRETV (ΣSRETV) and TLSRE (ΣTLSRE) for all detected lesions per patient were calculated. Progression-free survival (PFS) was set as primary endpoint. Kaplan-Meier survival analysis, log-rank test, and Cox's proportional hazard model were used for statistical analysis. RESULTS: Univariate analyses revealed significant difference of PFS for WHO tumor grade and ΣSRETV (P < 0.05), while there were no significant differences in age, sex, SUVmax, and ΣTLSRE (P > 0.05). Multivariate analysis identified WHO tumor grade and ΣSRETV as independent predictors of PFS. CONCLUSION: ΣSRETV calculated from 68Ga-DOTATATE PET/CT may have prognostic value of PFS in WD-NET patients.
PURPOSE: To evaluate the prognostic value of volumetric parameters calculated from 68Ga-1,4,7,10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA)-Thr3-octreotate (68Ga-DOTATATE) positron emission tomography/computed tomography (PET/CT) in patients with well-differentiated neuroendocrine tumor (WD-NET). METHODS: Ninety-two patients (44 men and 48 women, mean age of 59.5-year-old) with pathologically confirmed WD-NET (grades 1 or 2) were enrolled in a prospective expanded access protocol. Selected data was analyzed retrospectively for this project. Maximum standardized uptake value (SUVmax) in the lesion with the highest 68Ga-DOTATATE uptake was measured and recorded for each patient. In addition, two volumetric parameters, namely, somatostatin receptor expressing tumor volume (SRETV) and total lesion somatostatin receptor expression (TLSRE), were calculated in each 68Ga-DOTATATE-avid lesion. SRETV was defined as tumor volume with higher 68Ga-DOTATATE uptake than the 50% of SUVmax within the volume of interest (VOI) for each lesion. TLSRE was calculated by multiplying SRETV and mean SUV within the same VOI. Thereafter, the sum of SRETV (ΣSRETV) and TLSRE (ΣTLSRE) for all detected lesions per patient were calculated. Progression-free survival (PFS) was set as primary endpoint. Kaplan-Meier survival analysis, log-rank test, and Cox's proportional hazard model were used for statistical analysis. RESULTS: Univariate analyses revealed significant difference of PFS for WHO tumor grade and ΣSRETV (P < 0.05), while there were no significant differences in age, sex, SUVmax, and ΣTLSRE (P > 0.05). Multivariate analysis identified WHO tumor grade and ΣSRETV as independent predictors of PFS. CONCLUSION: ΣSRETV calculated from 68Ga-DOTATATE PET/CT may have prognostic value of PFS in WD-NET patients.
Authors: Alexander R Haug; Christoph J Auernhammer; Björn Wängler; Gerwin P Schmidt; Christopher Uebleis; Burkhard Göke; Paul Cumming; Peter Bartenstein; Reinhold Tiling; Marcus Hacker Journal: J Nucl Med Date: 2010-08-18 Impact factor: 10.057
Authors: Holly M Thompson; Ryogo Minamimoto; Mehran Jamali; Amir Barkhodari; Rie von Eyben; Andrei Iagaru Journal: Clin Nucl Med Date: 2016-07 Impact factor: 7.794
Authors: Ho Seong Kim; Joon Young Choi; Dong Wook Choi; Ho Yeong Lim; Joo Hee Lee; Sun Pyo Hong; Young Seok Cho; Kyung-Han Lee; Byung-Tae Kim Journal: Nucl Med Mol Imaging Date: 2014-02-07
Authors: Arvind Dasari; Chan Shen; Daniel Halperin; Bo Zhao; Shouhao Zhou; Ying Xu; Tina Shih; James C Yao Journal: JAMA Oncol Date: 2017-10-01 Impact factor: 31.777
Authors: David Lh Chan; Nick Pavlakis; Geoffrey P Schembri; Elizabeth J Bernard; Edward Hsiao; Aimee Hayes; Tristan Barnes; Connie Diakos; Mustafa Khasraw; Jaswinder Samra; Enid Eslick; Paul J Roach; Alexander Engel; Stephen J Clarke; Dale L Bailey Journal: Theranostics Date: 2017-03-01 Impact factor: 11.556
Authors: Ryan P Reddy; C Ross Schmidtlein; Romina G Giancipoli; Audrey Mauguen; Daniel LaFontaine; Heiko Schoder; Lisa Bodei Journal: J Nucl Med Date: 2021-11-12 Impact factor: 11.082
Authors: Esben Andreas Carlsen; Camilla Bardram Johnbeck; Tina Binderup; Mathias Loft; Andreas Pfeifer; Jann Mortensen; Peter Oturai; Annika Loft; Anne Kiil Berthelsen; Seppo W Langer; Ulrich Knigge; Andreas Kjaer Journal: J Nucl Med Date: 2020-02-28 Impact factor: 10.057
Authors: Esben Andreas Carlsen; Camilla Bardram Johnbeck; Mathias Loft; Andreas Pfeifer; Peter Oturai; Seppo W Langer; Ulrich Knigge; Claes Nøhr Ladefoged; Andreas Kjaer Journal: J Nucl Med Date: 2021-02-26 Impact factor: 11.082
Authors: Simone Krebs; Joseph A O'Donoghue; Evan Biegel; Bradley J Beattie; Diane Reidy; Serge K Lyashchenko; Jason S Lewis; Lisa Bodei; Wolfgang A Weber; Neeta Pandit-Taskar Journal: Eur J Nucl Med Mol Imaging Date: 2020-05-06 Impact factor: 9.236
Authors: Thorsten Derlin; Natalia Bogdanova; Fiona Ohlendorf; Dhanya Ramachandran; Rudolf A Werner; Tobias L Ross; Hans Christiansen; Frank M Bengel; Christoph Henkenberens Journal: Cancers (Basel) Date: 2021-03-25 Impact factor: 6.639